These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

924 related items for PubMed ID: 9336349

  • 1. Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716.
    Major TC, Keiser JA.
    J Pharmacol Exp Ther; 1997 Oct; 283(1):402-10. PubMed ID: 9336349
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor.
    Dahring TK, Lu GH, Hamby JM, Batley BL, Kraker AJ, Panek RL.
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1446-56. PubMed ID: 9190882
    [Abstract] [Full Text] [Related]

  • 3. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
    Panek RL, Lu GH, Klutchko SR, Batley BL, Dahring TK, Hamby JM, Hallak H, Doherty AM, Keiser JA.
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019
    [Abstract] [Full Text] [Related]

  • 4. Mechanisms of inhibition by heparin of PDGF stimulated MAP kinase activation in vascular smooth muscle cells.
    Pukac LA, Carter JE, Ottlinger ME, Karnovsky MJ.
    J Cell Physiol; 1997 Jul; 172(1):69-78. PubMed ID: 9207927
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
    Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ, Lydon NB.
    Cancer Res; 1996 Jan 01; 56(1):100-4. PubMed ID: 8548747
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of basic fibroblast growth factor-mediated tyrosine phosphorylation and protein synthesis by PD 145709, a member of the 2-thioindole class of tyrosine kinase inhibitors.
    Fry DW, Nelson JM.
    Anticancer Drug Des; 1995 Dec 01; 10(8):607-22. PubMed ID: 8595121
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.
    Shawver LK, Schwartz DP, Mann E, Chen H, Tsai J, Chu L, Taylorson L, Longhi M, Meredith S, Germain L, Jacobs JS, Tang C, Ullrich A, Berens ME, Hersh E, McMahon G, Hirth KP, Powell TJ.
    Clin Cancer Res; 1997 Jul 01; 3(7):1167-77. PubMed ID: 9815796
    [Abstract] [Full Text] [Related]

  • 8. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.
    Panek RL, Lu GH, Dahring TK, Batley BL, Connolly C, Hamby JM, Brown KJ.
    J Pharmacol Exp Ther; 1998 Jul 01; 286(1):569-77. PubMed ID: 9655904
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation.
    Lipson KE, Pang L, Huber LJ, Chen H, Tsai JM, Hirth P, Gazit A, Levitzki A, McMahon G.
    J Pharmacol Exp Ther; 1998 May 01; 285(2):844-52. PubMed ID: 9580635
    [Abstract] [Full Text] [Related]

  • 10. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N.
    J Pharm Belg; 1997 May 01; 52(2):88-96. PubMed ID: 9193132
    [Abstract] [Full Text] [Related]

  • 11. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation.
    Kovalenko M, Gazit A, Böhmer A, Rorsman C, Rönnstrand L, Heldin CH, Waltenberger J, Böhmer FD, Levitzki A.
    Cancer Res; 1994 Dec 01; 54(23):6106-14. PubMed ID: 7954456
    [Abstract] [Full Text] [Related]

  • 12. Signal transduction by basic fibroblast growth factor in rat osteoblastic Py1a cells.
    Hurley MM, Marcello K, Abreu C, Kessler M.
    J Bone Miner Res; 1996 Sep 01; 11(9):1256-63. PubMed ID: 8864900
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor.
    Reddy KB, Mangold GL, Tandon AK, Yoneda T, Mundy GR, Zilberstein A, Osborne CK.
    Cancer Res; 1992 Jul 01; 52(13):3636-41. PubMed ID: 1617636
    [Abstract] [Full Text] [Related]

  • 14. Interrelationships of platelet-derived growth factor isoform-induced changes in c-fos expression, intracellular free calcium, and mitogenesis.
    Diliberto PA, Bernacki SH, Herman B.
    J Cell Biochem; 1990 Sep 01; 44(1):39-53. PubMed ID: 2135398
    [Abstract] [Full Text] [Related]

  • 15. Differential effects of lovastatin on mitogen induced calcium influx in human cultured vascular smooth muscle cells.
    Clunn GF, Lymn JS, Schachter M, Hughes AD.
    Br J Pharmacol; 1997 Aug 01; 121(8):1789-95. PubMed ID: 9283719
    [Abstract] [Full Text] [Related]

  • 16. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
    Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Regenass U, Lydon NB.
    Proc Natl Acad Sci U S A; 1995 Mar 28; 92(7):2558-62. PubMed ID: 7708684
    [Abstract] [Full Text] [Related]

  • 17. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
    Traxler PM, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N.
    J Med Chem; 1996 Jun 07; 39(12):2285-92. PubMed ID: 8691423
    [Abstract] [Full Text] [Related]

  • 18. Antiproliferative action of cudraflavone B, isolated from Cudrania tricuspidata, through the downregulation of pRb phosphorylation in aortic smooth muscle cell proliferation signaling.
    Kim TJ, Han HJ, Lim Y, Song MC, Kim J, Hong JT, Yoo HS, Pyo MY, Hwang BY, Lee MK, Yun YP.
    J Cardiovasc Pharmacol; 2009 Apr 07; 53(4):341-8. PubMed ID: 19295442
    [Abstract] [Full Text] [Related]

  • 19. Pregnancy-stimulated growth of vascular smooth muscle cells: importance of protein kinase C-dependent synergy between estrogen and platelet-derived growth factor.
    Keyes LE, Moore LG, Walchak SJ, Dempsey EC.
    J Cell Physiol; 1996 Jan 07; 166(1):22-32. PubMed ID: 8557771
    [Abstract] [Full Text] [Related]

  • 20. Protamine inhibits platelet derived growth factor receptor activity but not epidermal growth factor activity.
    Huang JS, Nishimura J, Huang SS, Deuel TF.
    J Cell Biochem; 1984 Jan 07; 26(4):205-20. PubMed ID: 6099364
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.